ADCT — Adc Therapeutics Share News
0.000.00%
Last trade - 00:00- $190.22m
- $387.28m
- $81.36m
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million
Brief: ADC Therapeutics Announces Amended Healthcare Royalty Financing Agreement
Brief: Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta
Brief: ADC Therapeutics SA - Selling Shareholders May Offer 14.7 Million Common Shares - SEC Filing
ADC Therapeutics Q3 net income beats analyst expectations
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics SA expected to post a loss of 47 cents a share - Earnings Preview
Brief: Adc Therapeutics Announces $100 Mln Private Placement Extending Expected Cash Runway Into 2028
ADC Therapeutics SA reports results for the quarter ended March 31 - Earnings Summary
ADC Therapeutics SA expected to post a loss of 40 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 40 cents a share - Earnings Preview